AI Tokens
Stock Analysis on Net

Edwards Lifesciences Corp. (NYSE:EW)

This company has been moved to the archive! The financial data has not been updated since February 14, 2022.

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin

Microsoft Excel

Two-Component Disaggregation of ROE

Edwards Lifesciences Corp., decomposition of ROE

Microsoft Excel
ROE = ROA × Financial Leverage
Dec 31, 2021 25.76% = 17.68% × 1.46
Dec 31, 2020 18.00% = 11.38% × 1.58
Dec 31, 2019 25.24% = 16.14% × 1.56
Dec 31, 2018 23.00% = 13.57% × 1.70
Dec 31, 2017 19.74% = 10.25% × 1.93

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


The Return on Equity (ROE) exhibited a generally upward trajectory between 2017 and 2021, rising from 19.74% to a peak of 25.76%. Although a notable contraction occurred in 2020, where ROE declined to 18.00%, the subsequent recovery in 2021 surpassed all previous levels in the analyzed period. This overall growth in shareholder returns was achieved despite a consistent reduction in financial leverage.

Return on Assets (ROA) Trends
The ROA demonstrated significant growth from 10.25% in 2017 to 17.68% in 2021. A period of steady improvement was observed through 2019, followed by a temporary decline to 11.38% in 2020. The sharp rebound in 2021 indicates an increase in operational efficiency and a greater capacity to generate earnings from the asset base.
Financial Leverage Dynamics
A clear downward trend in financial leverage is evident, moving from 1.93 in 2017 to 1.46 by 2021. This suggests a strategic shift toward a less leveraged capital structure and a reduction in the reliance on debt to finance assets over the five-year duration.
Drivers of ROE Performance
The two-component disaggregation reveals that the expansion of ROE was driven exclusively by improvements in asset productivity (ROA) rather than financial engineering. Because the financial leverage ratio declined steadily, the increasing ROE indicates that the gains in operational profitability more than offset the reduction in the leverage multiplier. The performance in 2021 is particularly noteworthy, as the highest ROE was achieved alongside the lowest level of leverage in the period, signaling a high-quality growth profile rooted in fundamental operational strength.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Three-Component Disaggregation of ROE

Edwards Lifesciences Corp., decomposition of ROE

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Dec 31, 2021 25.76% = 28.73% × 0.62 × 1.46
Dec 31, 2020 18.00% = 18.77% × 0.61 × 1.58
Dec 31, 2019 25.24% = 24.08% × 0.67 × 1.56
Dec 31, 2018 23.00% = 19.40% × 0.70 × 1.70
Dec 31, 2017 19.74% = 16.99% × 0.60 × 1.93

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


The Return on Equity (ROE) for the period between 2017 and 2021 exhibited an overall upward trajectory, growing from 19.74% to 25.76%. Although a notable contraction occurred in 2020, where ROE fell to 18.00%, the metric recovered strongly in 2021, reaching its five-year peak. The drivers of this performance vary across the three components of the DuPont analysis.

Net Profit Margin
The net profit margin served as the primary driver of ROE growth. A consistent expansion is observed, moving from 16.99% in 2017 to 28.73% in 2021. Despite a temporary decline to 18.77% in 2020, the sharp increase in 2021 indicates significant improvements in cost management or pricing power, contributing substantially to the overall return for shareholders.
Asset Turnover
Asset utilization remained relatively stable with a slight downward bias over the long term. After peaking at 0.70 in 2018, the ratio declined to 0.62 by 2021. This suggests that the company's ability to generate sales from its asset base has not been the catalyst for the increase in ROE, and may instead represent an increase in the asset base that has not yet been fully matched by proportional revenue growth.
Financial Leverage
A steady decline in financial leverage is evident throughout the period, falling from 1.93 in 2017 to 1.46 in 2021. This downward trend indicates a strategic reduction in the reliance on debt to finance assets, thereby reducing the financial risk profile of the organization.

The synthesis of these components reveals that the growth in ROE is driven by operational profitability rather than financial engineering. The increase in shareholder returns was achieved despite a decreasing leverage ratio and stagnant asset turnover, highlighting that the expansion of the net profit margin was the sole dominant force in elevating the ROE.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Five-Component Disaggregation of ROE

Edwards Lifesciences Corp., decomposition of ROE

Microsoft Excel
ROE = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Financial Leverage
Dec 31, 2021 25.76% = 0.88 × 0.99 × 32.88% × 0.62 × 1.46
Dec 31, 2020 18.00% = 0.90 × 0.98 × 21.26% × 0.61 × 1.58
Dec 31, 2019 25.24% = 0.90 × 0.98 × 27.30% × 0.67 × 1.56
Dec 31, 2018 23.00% = 0.95 × 0.96 × 21.26% × 0.70 × 1.70
Dec 31, 2017 19.74% = 0.56 × 0.98 × 30.80% × 0.60 × 1.93

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


The Return on Equity (ROE) exhibited a general upward trajectory between 2017 and 2021, rising from 19.74% to a peak of 25.76%. Despite a notable contraction in 2020 to 18.00%, the overall period is characterized by volatility in operational margins and a strategic reduction in financial leverage.

Tax and Interest Burdens
A significant increase in the tax burden ratio occurred between 2017 and 2018, moving from 0.56 to 0.95, before stabilizing between 0.88 and 0.90 in subsequent years. This suggests a substantial improvement in after-tax profit retention. The interest burden remained consistently high and stable, ranging from 0.96 to 0.99, indicating that interest expenses have a negligible impact on operating earnings.
Operational Performance
The EBIT margin demonstrated significant volatility, with troughs of 21.26% in 2018 and 2020 and a peak of 32.88% in 2021. This variability indicates fluctuating operating profitability. Meanwhile, asset turnover remained relatively stable, peaking at 0.70 in 2018 and settling at 0.62 by 2021, suggesting a consistent relationship between total assets and revenue generation.
Financial Leverage
A consistent downward trend is observed in financial leverage, which declined from 1.93 in 2017 to 1.46 in 2021. This indicates a systematic reduction in the use of debt to finance assets, shifting the company toward a more equity-heavy capital structure.
ROE Drivers
The growth in ROE was not driven by financial leverage, which trended downward, but rather by improvements in the tax burden and a strong recovery in the EBIT margin by 2021. The dip in ROE during 2020 correlates directly with a decrease in the EBIT margin and a slight decline in asset turnover, highlighting that the company's equity returns are highly sensitive to operating efficiency.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Two-Component Disaggregation of ROA

Edwards Lifesciences Corp., decomposition of ROA

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Dec 31, 2021 17.68% = 28.73% × 0.62
Dec 31, 2020 11.38% = 18.77% × 0.61
Dec 31, 2019 16.14% = 24.08% × 0.67
Dec 31, 2018 13.57% = 19.40% × 0.70
Dec 31, 2017 10.25% = 16.99% × 0.60

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


The Return on Assets (ROA) demonstrated a general upward trajectory between 2017 and 2021, increasing from 10.25% to 17.68%. While a notable contraction occurred in 2020, where ROA fell to 11.38%, the recovery in 2021 marked the highest performance level within the analyzed period. The disaggregation of ROA indicates that this overall growth is driven primarily by profitability margins rather than improvements in asset efficiency.

Net Profit Margin
A strong growth trend is observed in the Net Profit Margin, which rose from 16.99% in 2017 to 28.73% in 2021. This expansion indicates a significant increase in the ability to convert revenue into net income. The margin experienced a temporary decline in 2020 to 18.77%, closely mirroring the dip in overall ROA, before rebounding sharply in the final year of the period.
Asset Turnover
Asset Turnover remained relatively stable with a slight downward bias over the five-year duration. After reaching a peak of 0.70 in 2018, the ratio gradually declined to 0.62 by 2021. This indicates that the growth in ROA was not supported by increased operational efficiency in generating sales from the asset base, but rather occurred despite a stagnation in asset productivity.
ROA Driver Analysis
The two-component analysis reveals a clear divergence between margin performance and asset utilization. The expansion of ROA is almost exclusively attributable to the increase in the Net Profit Margin. The relative stability and slight decline in Asset Turnover suggest that the return on assets is being optimized through enhanced pricing power or cost management rather than through the intensification of asset usage or sales volume growth relative to the asset base.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Four-Component Disaggregation of ROA

Edwards Lifesciences Corp., decomposition of ROA

Microsoft Excel
ROA = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover
Dec 31, 2021 17.68% = 0.88 × 0.99 × 32.88% × 0.62
Dec 31, 2020 11.38% = 0.90 × 0.98 × 21.26% × 0.61
Dec 31, 2019 16.14% = 0.90 × 0.98 × 27.30% × 0.67
Dec 31, 2018 13.57% = 0.95 × 0.96 × 21.26% × 0.70
Dec 31, 2017 10.25% = 0.56 × 0.98 × 30.80% × 0.60

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


The Return on Assets (ROA) exhibited an overall upward trajectory between 2017 and 2021, rising from 10.25% to 17.68%. While the growth was consistent through 2019, a notable contraction occurred in 2020, where ROA fell to 11.38%, before recovering strongly to its five-year peak in 2021.

Tax Burden
A substantial increase in the tax burden ratio is observed between 2017 and 2018, moving from 0.56 to 0.95. This indicates a significant improvement in the proportion of pre-tax income retained as net income. From 2018 to 2021, this ratio remained relatively stable, fluctuating slightly between 0.88 and 0.95.
Interest Burden
The interest burden remained consistently high throughout the period, ranging from 0.96 to 0.99. These values, being close to unity, suggest that interest expenses have a negligible impact on the company's overall profitability, reflecting a conservative leverage position or low financing costs relative to operating income.
EBIT Margin
Operating profitability demonstrated significant volatility. The EBIT margin declined from 30.80% in 2017 to 21.26% in 2018, recovered to 27.30% in 2019, and dipped again to 21.26% in 2020. A sharp expansion occurred in 2021, reaching 32.88%, which served as a primary catalyst for the increase in ROA during that year.
Asset Turnover
Asset utilization remained relatively stable, with the ratio fluctuating within a narrow band between 0.60 and 0.70. A peak in efficiency was noted in 2018 at 0.70, followed by a gradual decline and stabilization around 0.62 by 2021. This suggests that the growth in ROA was driven more by margin expansion and tax efficiencies than by increases in asset productivity.

In summary, the expansion of the ROA over the analyzed period was primarily driven by a marked improvement in the tax burden ratio starting in 2018 and a strong recovery in EBIT margins by 2021. The stability of the interest burden and the relative constancy of asset turnover indicate that financial leverage and operational asset efficiency were not the primary drivers of the observed performance shifts.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Disaggregation of Net Profit Margin

Edwards Lifesciences Corp., decomposition of net profit margin ratio

Microsoft Excel
Net Profit Margin = Tax Burden × Interest Burden × EBIT Margin
Dec 31, 2021 28.73% = 0.88 × 0.99 × 32.88%
Dec 31, 2020 18.77% = 0.90 × 0.98 × 21.26%
Dec 31, 2019 24.08% = 0.90 × 0.98 × 27.30%
Dec 31, 2018 19.40% = 0.95 × 0.96 × 21.26%
Dec 31, 2017 16.99% = 0.56 × 0.98 × 30.80%

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


The net profit margin exhibits an overall upward trajectory over the five-year period, increasing from 16.99% in 2017 to 28.73% in 2021. While the progression was not linear, specifically experiencing a contraction in 2020, the terminal margin represents a significant expansion in bottom-line profitability relative to revenue.

Net Profit Margin Trends
Profitability grew steadily between 2017 and 2019, reaching 24.08%, before declining to 18.77% in 2020. A sharp recovery occurred in 2021, resulting in the highest margin of the period at 28.73%.
Operating Efficiency (EBIT Margin)
The EBIT margin shows considerable volatility, acting as a primary driver of the net profit fluctuations. A notable decline occurred in 2018 and again in 2020, with the margin hitting a low of 21.26% in both years. This was followed by a strong rebound to 32.88% in 2021, indicating a substantial improvement in operational efficiency and cost management toward the end of the period.
Tax Burden Impact
A significant shift is observed in the tax burden ratio, which rose sharply from 0.56 in 2017 to 0.95 in 2018. The 2017 value indicates a period of exceptionally low effective taxation or a one-time tax benefit that artificially boosted the net margin relative to the EBIT margin. From 2018 through 2021, the ratio stabilized between 0.88 and 0.95, suggesting a normalization of the company's tax environment.
Interest Burden Stability
The interest burden remained remarkably stable, hovering between 0.96 and 0.99 throughout the entire analysis period. The proximity of these values to 1.0 indicates that interest expenses have a negligible impact on the conversion of operating profit to net income, suggesting a conservative leverage profile or highly manageable debt service costs.

In summary, the expansion of the net profit margin is primarily attributed to a significant recovery in operating margins by 2021, despite the normalization of tax burdens following 2017. The consistency of the interest burden indicates that financial leverage was not a contributing factor to the observed volatility in profitability.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?